This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PneuGEM
PneuGEM is a Mimopath-based vaccine to prevent diseases caused by pneumococcal bacteria.
The Mucosis Mimopath technology stimulates the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune system. The core of the Mimopath technology is the Bacterium-Like Particle (BLP). There are two modes of application of the BLPs. The first is an Add & Mix approach in which the immune stimulating properties of the BLPs are used to improve existing vaccines and to enable a mucosal route of administration. The second is a Bound approach in which the BLPs not only act as immunostimulant but also as a carrier for the subunit antigen(s). The binding of the antigens is achieved by a linker domain called Protan that binds to the surface of the BLPs.
Pink Sheet Weekly Trademark Review Sept. 15, 2015
Additional information available to subscribers only: